NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

Gary,

My conjecture it should be a stream of good news. I should say a stream of exciting news. Not every one in investor field knows about NWBO. But I am so certain that all the BPs which have business in oncology know NWBO and they know NWBO a lot better than us. The partnership is certain. It is just the width and depth of the partnership that we need to see. Is the partnership from both the public sectors and private sectors such as all the BPs in oncology business? We will find out after the approval. As an illustration of my point on the possibility that all the BPs in oncology business might like to have partnership with NWBO, take Takeda as an example.

Here is the leadership on oncology from Takeda.
https://www.takedaoncology.com/about/leadership/

Here is the resume of President, Global Oncology Business Unit. Teresa Bitetti used to work at BMS for 18 years before she joined Takeda. I suspect it is commonsense that she would suggest Takeda to reach LP, sign NDA and take a look the first hand data on DCVax-L.

Teresa Bitetti is President of the Global Oncology Business Unit at Takeda, the largest biopharma employer in Massachusetts. Teresa oversees an in-line global portfolio consisting of therapies in hematological malignancies and lung cancer. Given her strong expertise and experience in product commercialization and launches, Teresa understands the importance of close alignment with R&D to accelerate the science and to bring meaningful medicines to patients quickly and efficiently.

Teresa has extensive experience in the oncology field and has been highly recognized for her adept ability to inspire and mobilize teams to deliver exceptional performance throughout her career. Before joining Takeda, Teresa was Senior Vice President, Head of Worldwide Oncology Commercialization at Bristol Myers Squibb (BMS), where she spearheaded the acceleration and augmentation of the oncology pipeline and significantly enhanced the long-term strategic direction of the immuno-oncology portfolio.

During her 23 years at BMS, other key leadership roles included: Senior Vice President and Head of U.S. Oncology – where she managed the launch of the blockbuster drug, Opdivo, and the entire US portfolio – President and GM of BMS Canada, and Worldwide Head of the BMS Virology business. Before BMS, Teresa held various roles of increasing responsibility at Mobil Oil Corporation, where she was part of the Capital Markets Group and responsible for the investment of Mobil’s worldwide pension assets.

Teresa is a member of the Board of Directors of Osmol Therapeutics, a privately held biopharmaceutical company focused on developing a treatment to prevent chemotherapy-induced peripheral neuropathy. She is also on the Board of Directors for Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer.

Teresa holds an MBA in Finance from the Darden School of Business at the University of Virginia and a BA in Classical Civilization from Wellesley College. She lives in Cambridge and has two children.